基本信息
浏览量:25
职业迁徙
个人简介
Dr. Rosenblum has been at ActivX since January 2001. He is responsible for overseeing biological aspects of the company’s drug discovery programs, spanning target selection to submitting reports to FDA.
He was one of the original scientists at the company, and has been involved in many facets of the company’s evolution. He was ActivX's project leader for a collaboration with Kyorin that resulted in the discovery and development of the DPP-4 inhibitor bisegliptin (KRP-104), which has completed worldwide Phase 2 clinical study. Jonathan also served as the Principal Investigator for an SBIR grant (Phase 1 and Phase 2) from the National Institutes of Health, and has served as a study section member at the NIH.
Prior to ActivX, Jonathan trained as an NIH postdoctoral fellow in the laboratory of Nobel Laureate Günter Blobel at the Rockefeller University. While at Rockefeller, Jonathan used proteomics and molecular cell biology to characterize mechanisms of nuclear protein transport. Prior to Rockefeller, Jonathan received his Ph.D. in Macromolecular and Cellular Structure and Chemistry as a National Science Foundation fellow at The Scripps Research Institute. Jonathan received a Bachelor of Arts degree in chemistry, magna cum laude, from the University of Pennsylvania, where he was also elected to Phi Beta Kappa, having been a Benjamin Franklin Scholar.
Specialties: Drug discovery, biochemistry, enzymology, high throughput screening, proteomics, proteases, kinases
研究兴趣
论文共 43 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Toshiyuki Matsui,Motomichi Fujita,Yuji Ishibashi,Tyzoon Nomanbhoy,Jonathan S Rosenblum,Michiaki Nagasawa
Open Forum Infectious Diseasesno. Supplement_1 (2021)
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn